ATE273007T1 - Behandlung der schizophrenie und der psychose - Google Patents

Behandlung der schizophrenie und der psychose

Info

Publication number
ATE273007T1
ATE273007T1 AT98924064T AT98924064T ATE273007T1 AT E273007 T1 ATE273007 T1 AT E273007T1 AT 98924064 T AT98924064 T AT 98924064T AT 98924064 T AT98924064 T AT 98924064T AT E273007 T1 ATE273007 T1 AT E273007T1
Authority
AT
Austria
Prior art keywords
psychosis
schizophrenia
treatment
diseases
methylpyridine
Prior art date
Application number
AT98924064T
Other languages
German (de)
English (en)
Inventor
Frank Sams-Dodd
Arnt Jorn
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Application granted granted Critical
Publication of ATE273007T1 publication Critical patent/ATE273007T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT98924064T 1997-05-29 1998-05-28 Behandlung der schizophrenie und der psychose ATE273007T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK62097 1997-05-29
PCT/DK1998/000220 WO1998053820A1 (en) 1997-05-29 1998-05-28 Treatment of schizophrenia and psychosis

Publications (1)

Publication Number Publication Date
ATE273007T1 true ATE273007T1 (de) 2004-08-15

Family

ID=8095640

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98924064T ATE273007T1 (de) 1997-05-29 1998-05-28 Behandlung der schizophrenie und der psychose

Country Status (10)

Country Link
US (1) US6297262B1 (OSRAM)
EP (1) EP1014974B1 (OSRAM)
JP (1) JP2002500651A (OSRAM)
AT (1) ATE273007T1 (OSRAM)
AU (1) AU7639598A (OSRAM)
DE (1) DE69825605T2 (OSRAM)
ES (1) ES2227836T3 (OSRAM)
PT (1) PT1014974E (OSRAM)
WO (1) WO1998053820A1 (OSRAM)
ZA (1) ZA984633B (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091357B2 (en) * 2001-12-26 2006-08-15 University Of Kentucky Research Foundation Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies
DK1766077T3 (da) 2004-06-21 2012-07-16 Univ Leland Stanford Junior Differentielt udtrykte gener og veje i bipolar forstyrrelse og/eller alvorlig depressiv forstyrrelse
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
EP1951908B1 (en) 2005-11-12 2013-08-07 The Board of Trustees of The Leland Stanford Junior University Fgf2-related methods for diagnosing and treating depression
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CA2875674A1 (en) 2012-06-05 2013-12-12 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating psychiatric disorders or symptoms thereof using ncam peptide mimetics
WO2017147104A1 (en) * 2016-02-24 2017-08-31 Chase Pharmaceuticals Corporation Muscarinic m2-antagonist combinations
WO2018039159A1 (en) * 2016-08-22 2018-03-01 Chase Pharmaceuticals Corporation Muscarinic m2-antagonist combination

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE845612A (fr) 1976-03-23 1977-02-28 Derives de tetrazole-5-carboxamide et leur preparation
DE3421072A1 (de) 1984-06-06 1985-12-12 Heinrich Mack Nachf., 7918 Illertissen 1,4:3,6-dianhydro-hexit-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
EP0261763B1 (en) 1986-06-27 1994-02-09 Beecham Group Plc Novel bridged bicyclic N-heterocycles
IL83275A (en) 1986-09-08 1994-02-27 Novo Nordisk As Substituted 1, 2, 4- oxadiazolyl piperidine compounds, their preparation and pharmaceutical compositions containing them
GB8714789D0 (en) 1987-06-24 1987-07-29 Lundbeck & Co As H Heterocyclic compounds
GB8717446D0 (en) 1987-07-23 1987-08-26 Merck Sharp & Dohme Chemical compounds
US5405853A (en) 1987-09-10 1995-04-11 Merck Sharpe & Dohme Ltd. Thiadiazoles useful in the treatment of senile dementia
US5328925A (en) 1989-02-22 1994-07-12 Novo Nordisk A/S Piperidine compounds and their use
US5043345A (en) 1989-02-22 1991-08-27 Novo Nordisk A/S Piperidine compounds and their preparation and use
US5073560A (en) 1990-07-20 1991-12-17 Fisons Corporation Spiro-isoxazolidine derivatives as cholinergic agents
IE922270A1 (en) 1991-07-26 1993-01-27 Akzo Nv Pyrazole derivatives
US5330994A (en) 1992-03-24 1994-07-19 Warner-Lambert Company Tetrahydropyridine isoxazoline derivatives
AU674541B2 (en) 1992-08-31 1997-01-02 University Of Florida Research Foundation, Inc. Anabaseine derivatives useful in the treatment of degenerative diseases of the nervous system
CZ181493A3 (en) 1992-09-10 1994-03-16 Lilly Co Eli The use of rhodanine derivative for the preparation of a pharmaceutical composition reducing level of sugar in blood and for treating alzheimer's disease
DK0734259T3 (da) 1993-08-19 2002-09-30 Novo Nordisk As Antipsykotisk fremgangsmåde
US5705512A (en) 1994-11-10 1998-01-06 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5691365A (en) 1995-07-18 1997-11-25 University Of Kentucky Research Foundation Nicotinic receptor antagonists in the treatment of neuropharmacological disorders
US5756501A (en) 1995-12-13 1998-05-26 American Home Products Corporation Saturated and unsaturated pyridazino 4,5-B! indolizines useful as antidementia agents
US5739119A (en) 1996-11-15 1998-04-14 Galli; Rachel L. Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA

Also Published As

Publication number Publication date
PT1014974E (pt) 2004-12-31
EP1014974A1 (en) 2000-07-05
EP1014974B1 (en) 2004-08-11
AU7639598A (en) 1998-12-30
DE69825605T2 (de) 2005-09-15
ES2227836T3 (es) 2005-04-01
DE69825605D1 (de) 2004-09-16
ZA984633B (en) 1998-12-11
JP2002500651A (ja) 2002-01-08
US6297262B1 (en) 2001-10-02
WO1998053820A1 (en) 1998-12-03

Similar Documents

Publication Publication Date Title
DE69825605D1 (de) Behandlung der schizophrenie und der psychose
NO965377L (no) Indolinonforbindelser for behandling av sykdommer
NO913765D0 (no) Fremgangsmaate for kontinuerlig fremstilling av tyggegummi.
NO995221D0 (no) Sulfonamider for behandling av endotelinmedierte sykdommer
NO924461D0 (no) Dipyridamol for behandling av proliferaktive sykdommer
NO20012995L (no) Forbindelser nyttige for behandling av inflammatoriske sykdommer
FI931226A7 (fi) Hitaasti vapautuvia koostumuksia periodontaalisen sairauden hoitamisek si
NO981911D0 (no) Anvendelse av rhodaninderivater for fremstilling av et medikament for behandling av Alzheimer's sykdom
NO912051L (no) Fremgangsmaate for fremstilling av azolderivater.
FI952721A7 (fi) Aine maksa-sappi-sairauksien hoitamiseksi
NO910395L (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme 4-isoxazolcarboxamidderivater.
NO953254D0 (no) Substituerte azolonderivater for behandling av sykdommer forårsaket av helikobakter
FI933902A7 (fi) Substituoidut sykloheksaanijohdannaiset sairauksien hoitamiseksi
DE69824576D1 (de) Verwendung von tetrahydropyridinderivaten zur herstellung von arzneimitteln zur behandlung demyelinisierender erkrankungen
DE69130586D1 (de) Behandlung von Pankreaskrankheit mit 15-keto-Prostaglandin E-Derivaten
ATE137116T1 (de) Behandlung von entzündlichen erkrankungen mit 15- ketoprostaglandinen
NO20002174D0 (no) FremgangsmÕte for fremstilling av tiazolidindion-derivater
DE69024744D1 (de) Behandlung der hepatobilären Erkrankung mit 15-Ketoprostaglandin-Derivaten
NO171851C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktivt 6-cyano-4-(1,2-dihydro-2-okso-pyrid-1-yl)-2,2-dimetylkromen
PT874843E (pt) 4-(1h-benzimidazol-2-il)¬1,4|diazepinos substituidos uteis para o tratamento de doencas alergicas
NO20023937D0 (no) Fremgangsmåte for fremstilling av substituert tiazolidindion
ATE261434T1 (de) Triptolid-derivate geeignet zur behandlung von autoimmunkrankheiten
NO913117D0 (no) Fremgangsmaate for behandling av benoedeleggende sykdommer.
NO20012612L (no) Isonipecotamider for behandlingen av integrin-formidlede sykdommer
DK0454429T3 (da) Anvendelse af 15-dehydroxy-16-oxoprostaglandinderivater til behandling af allergiske sygdomme

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1014974

Country of ref document: EP

REN Ceased due to non-payment of the annual fee